Keywords: M&A, Deal valuatioans, Pharma, Biotech, Empty pipelines, IMAP

Empty pipelines drive deal valuations in pharmaceuticals sector, say IMAP

Article | 10 May 2012

A drought of domestic growth opportunities and new products is inflating valuations for R&D companies as deal values ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in